Abstract
BackgroundAt present, in 30–35% systemic lupus erythematosus (SLE) patients antiphospholipid antibodies (aPL) are associated with the development of secondary antiphospholipid syndrome (APS), including venous and/or arterial thrombosis and other systemic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have